Comparative Renal Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist and Sodium–Glucose Cotransporter 2 Inhibitor in US Veterans with Type 2 Diabetes and CKD
Clinical Journal of the American Society of Nephrology · 29.09.2026
DOI: 10.2215/cjn.0000001244 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Journal of the American Society of Nephrology, online erschienen am 29.09.2026. Verfasst von Phyo Than Htoo und 5 weiteren Autor:innen. Beteiligte Einrichtung: New England Geriatric Research Education and Clinical Center, VA Boston Healthcare System, Boston, Massachusetts. Die Arbeit nennt 28 Literaturangaben. Gefördert von: Patient-Centered Outcomes Research Institute.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Key Points Comparative evidence for glucagon-like peptide-1 receptor agonist versus sodium–glucose cotransporter 2 inhibitor is limited in clinically complex older adults with type 2 diabetes and moderate-to-severe CKD. We compared the nephroprotective benefits of glucagon-like peptide-1 receptor agonist and sodium–glucose cotransporter 2 inhibitor in older US Veterans with type 2 diabetes and CKD stage 3–4. Glucagon-like peptide-1 receptor agonist showed similar risks of major kidney events and mortality, but higher risks of kidney function decline compared with sodium–glucose cotransporter 2 inhibitor.
Background
To address limited comparative evidence in older, clinically complex patients with type 2 diabetes and moderate-to-advanced CKD, we compared nephroprotective outcomes after glucagon-like peptide-1 receptor agonist (GLP-1 RA) versus sodium–glucose cotransporter 2 inhibitor (SGLT2i) initiation among US Veterans aged 65 years or older with type 2 diabetes and CKD stages 3–4 during 2016–2025.
Methods
Within the US Veterans Health Administration database, we identified individuals with type 2 diabetes and CKD stage 3–4 (eGFR 15 to 100 covariates including comorbidities, medications, clinical parameters, and laboratory results using propensity score matching weights, we estimated hazard ratios and rate differences (RDs). Analyses were stratified by CKD stages, hemoglobin A1c, and body mass index.
Results
We identified 28,365 GLP-1 RA and 78,354 SGLT2i initiators (mean [SD] age: 74 [6] years versus 76 [6] years). Over a median follow-up of 11 months, the weighted risks for the primary outcome were similar between treatment groups (hazard ratio [95% confidence interval]: 1.00 [0.94 to 1.07]; RD per 1000 person-years [95% confidence interval]: 0.0002 [−0.0037 to 0.0042]), mainly attributed to the similar risk for all-cause mortality. The risks of the secondary outcomes were higher in GLP-1 RA versus SGLT2i initiators, with higher risks for sustained kidney function decline and ESKD. Findings were consistent across variations in baseline CKD stage, history of cardiovascular disease, body mass index, and hemoglobin A1c level. Absolute RD for major kidney disease events and ESKD were larger in patients with more advanced CKD stages.
Conclusions
These findings suggest broadly comparable overall kidney and survival outcomes, with potential advantages of SGLT2is for the risks of kidney function decline and incident ESKD across metabolic subgroups in this older adult cohort.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- New England Geriatric Research Education and Clinical Center, VA Boston Healthcare System, Boston, Massachusetts.
- Merck & Co., Rahway, New Jersey.
- Division of Pharmacoepidemiology and Pharmacoeconomics, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts.
- Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine at UCLA, Los Angeles, California.
- Diabetes Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
- Division of Aging, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts.
ORCID-Profile: Phyo Than Htoo, Elisabetta Patorno, Ariela Orkaby, Julie M Paik
Förderung
- Patient-Centered Outcomes Research Institute
Zitieren
APA
Htoo, P. T., Patorno, E., Ortega-Montiel, J., Wexler, D. J., Orkaby, A., & Paik, J. M. (2026). Comparative Renal Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist and Sodium–Glucose Cotransporter 2 Inhibitor in US Veterans with Type 2 Diabetes and CKD. Clinical Journal of the American Society of Nephrology. https://doi.org/10.2215/cjn.0000001244
Vancouver
Htoo PT, Patorno E, Ortega-Montiel J, Wexler DJ, Orkaby A, Paik JM. Comparative Renal Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist and Sodium–Glucose Cotransporter 2 Inhibitor in US Veterans with Type 2 Diabetes and CKD. Clinical Journal of the American Society of Nephrology. 2026. doi:10.2215/cjn.0000001244
BibTeX
@article{Htoo2026,
author = {Htoo, Phyo Than and Patorno, Elisabetta and Ortega-Montiel, Janinne and Wexler, Deborah J and Orkaby, Ariela and Paik, Julie M},
title = {Comparative Renal Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist and Sodium–Glucose Cotransporter 2 Inhibitor in US Veterans with Type 2 Diabetes and CKD},
journal = {Clinical Journal of the American Society of Nephrology},
year = {2026},
doi = {10.2215/cjn.0000001244}
}
EUVIMED